NeoGenomics expects 3Q revenue of about $209 million, with next-generation sequencing revenue up roughly 28% year over year. The company says the preliminary figure is expected to lead to an increase in full-year revenue guidance at the midpoint, with details to come on the earnings call. The company also reiterated its full-year adjusted Ebitda guidance. NeoGenomics announced its guidance as the oncology diagnostic company named Warren Stone as incoming CEO.
This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.